Alphabet-owned company to begin human trials for cancer drug developed using AI
Founded in 2021, Isomorphic Labs is a subsidiary of Google parent Alphabet. It is currently preparing to dose the first patients with the AI-engineered drug in clinical trials and is 'staffing up' ahead of the trials, Isomorphic Labs president Colin Murdoch said in a recent interview with Fortune.
AlphaFold 3 is an AI tool that has been designed to help clinicians predict complex protein structures and molecular interactions. Using the tool, Isomorphic Labs were able to take major strides in terms of development of the drug.
Oncology drugs are essential medications as they play a vital role in the treatment of cancer. The drug either kills the cancer cells or slows their growth, allowing for further treatment. According to the World Health Organization (WHO), there were around 20 million new cancer cases and 9.7 million cancer-related deaths recorded in 2022. However, AI tools such as AlphaFold 3 are said to have vast potential in helping discover new types of drugs for treating terminal illnesses like cancer.
In March last year, Isomorphic Labs was able to raise over 600 million dollars through a funding round led by Thrive Capital. The company confirmed the use of this funding for the development of the AI drug-design engine, and helping toward their push to clinical trials.
'This funding will further turbocharge the development of our next-generation AI drug design engine, help us advance our own programmes into clinical development, and is a significant step forward towards our mission of one day solving all disease with the help of AI,' Demis Hassabis, the CEO of both Isomorphic Labs and Google DeepMind, said.
The company has inked partnerships worth over three billion dollars with pharma giants such as Novartis and Eli Lilly. The company's goal is to build a 'world-class drug design engine' that merges AI and human expertise to engineer new medications with a higher success rate at a cheaper cost for both manufacturers and consumers.
With the rapid rise of AI, other biotech companies such as Anima Biotech, Iktos, and Novo Nordisk are also harnessing the technology for more effective operations. Notably, Novo Nordisk signed a deal worth 2.76 billion dollars with Valo Health, aiming to make use of AI in their drug discovery process.
As per GlobalData statistics, over 3,000 drugs exist that have either been developed or re-purposed using AI technologies. While most of them are in the early stages of their development, they are still to be clinically tested on humans.
With its upcoming human tests, Isomorphic Labs could potentially pave the way for further progress in the biotech application of AI.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
5 hours ago
- India Today
OpenAI won gold at the world's toughest math exam. Why the Olympiad gold matters
In a jaw-dropping achievement for the world of artificial intelligence, OpenAI's latest experimental model has scored at the gold medal level at the International Mathematical Olympiad (IMO) -- one of the toughest math exams on the is the same event held on the Sunshine Coast in Australia where India won six medals this year and ranked 7th amongst 110 participating HITS GOLD IN THE WORLD'S TOUGHEST MATH TESTThe IMO is no ordinary competition. Since its launch in 1959 in Romania, it has become the gold standard for testing mathematical genius among high school students globally. Over two intense days, participants face a gruelling four-and-a-half-hour paper with only three questions each day. These are not your average exam questions -- they demand deep logic, creativity and problem-solving that, OpenAI's model solved five out of six questions correctly -- under the same testing conditions as human DOUBTED AI COULD DO THIS -- UNTIL NOWEven renowned mathematician Terence Tao -- an IMO gold medallist himself -- had doubts. In a podcast in June, he suggested that AI wasn't yet ready for the IMO level and should try simpler math contests first. But OpenAI has now proven otherwise."Also this model thinks for a *long* time. o1 thought for seconds. Deep Research for minutes. This one thinks for hours. Importantly, it's also more efficient with its thinking," Noam Brown from OpenAI wrote on LinkedIn."It's worth reflecting on just how fast AI progress has been, especially in math. In 2024, AI labs were using grade school math (GSM8K) as an eval in their model releases. Since then, we've saturated the (high school) MATH benchmark, then AIME, and now are at IMO gold," he THIS IS A BIG DEAL FOR GENERAL AIThis isn't just about math. OpenAI says this shows their AI model is breaking new ground in general-purpose reasoning. Unlike Google DeepMind's AlphaGeometry -- built just for geometry -- OpenAI's model is a general large language model that happens to be great at math too."Typically for these AI results, like in Go/Dota/Poker/Diplomacy, researchers spend years making an AI that masters one narrow domain and does little else. But this isn't an IMO-specific model. It's a reasoning LLM that incorporates new experimental general-purpose techniques," Brown explained in his Sam Altman called it 'a dream' when OpenAI began. 'This is a marker of how far AI has come in a decade.'advertisementBut before you get your hopes up, this high-performing AI isn't going public just yet. Altman confirmed it'll be 'many months' before this gold-level model is STILL REMAINNot everyone is fully convinced. AI expert Gary Marcus called the model's results 'genuinely impressive' -- but raised fair questions about training methods, how useful this is for the average person, and how much it all the win marks a huge leap in what artificial intelligence can do -- and how fast it's improving.- EndsMust Watch
Indian Express
a day ago
- Indian Express
OpenAI says its next big model can bring home Math Olympiad gold: A turning point?
The value of AI for most users today lies in its ability to generate coherent, conversational language by applying probability theory to massive datasets. However, a future where AI models drive advances in fields like cryptography and space exploration by solving complex, multi-step mathematical problems, is now one step closer to reality. OpenAI on Saturday, July 19, announced that its experimental AI reasoning model earned enough points on this year's International Math Olympiad (IMO) to win a gold medal. Started in 1959 in Romania, the IMO is widely considered to be one of the hardest, most prestigious math competitions in the world for high-school students. It is held over two days. Participants of the Olympiad take two exams, where they are expected to solve three math problems in each session within four-and-a-half hours. OpenAI's unreleased AI model took the IMO 2025 under these same conditions with no access to the internet or external tools. It read the official math problem statements and generated natural language proofs. The model solved five out of a total of six problems, achieving a gold medal-worthy score of 35/42, according to Alexander Wei, a member of OpenAI's technical staff. 'This underscores how fast AI has advanced in recent years. In 2021, my PhD advisor @JacobSteinhardthad me forecast AI math progress by July 2025. I predicted 30% on the MATH benchmark (and thought everyone else was too optimistic). Instead, we have IMO gold,' Wei wrote in a post on X. This isn't the first time a company has claimed that its AI model can match the performance of IMO gold medallists. Earlier this year, Google DeepMind introduced AlphaGeometry 2, a model specifically designed to solve complex geometry problems at a level comparable to a human Olympiad gold medallist. However, the performance of OpenAI's experimental model is seen as a step forward for general intelligence, not just task-specific AI systems. 'We reach this capability level not via narrow, task-specific methodology, but by breaking new ground in general-purpose reinforcement learning and test-time compute scaling,' Wei said. The model's success marks progress beyond traditional reinforcement learning (RL), which is a process used to train AI models through a system of clear, verifiable rewards and penalties. Instead, the model possibly demonstrates more flexible, general problem-solving abilities as it 'can craft intricate, watertight arguments at the level of human mathematicians.' Wei also acknowledged that 'IMO submissions are hard-to-verify, multi-page proofs.' Math proofs are made up of smaller, minor theorems called lemmas. OpenAI said that the AI-generated proofs to the problems were independently graded by three former IMO medalists, who finalised the model's score unanimously. However, Gary Marcus, a professor at New York University (NYU) and well-known critic of AI hype, pointed out that the results have not been independently verified by the organisers of the IMO. OpenAI's claims also come months after the US Defense Advanced Research Projects Agency DARPA launched a new initiative that looks to enlist researchers to find ways to conduct high-level mathematics research with an AI 'co-author.' In the past, DARPA was responsible for driving research that led to the creation of ARPANET, the precursor to the internet. An AI model that could reliably check proofs would save enormous amounts of time for mathematicians and help them be more creative. While some of these models might seem equipped to solve complex problems, they could also be prone to stumbling on simple questions like whether 9.11 is bigger than 9.9. Hence, they are said to have 'jagged intelligence', which is a term coined by OpenAI co-founder Andrej Karpathy. Reacting to the model's gold medal-worthy IMO score, OpenAI CEO Sam Altman said, 'This is an LLM doing math and not a specific formal math system; it is part of our main push towards general intelligence.' However, the ChatGPT-maker does not plan on releasing the experimental research model at least for the next several months despite its math capabilities.
India Today
4 days ago
- India Today
US employers to cut health benefits amid soaring weight-loss drug costs: Survey
More than half of large US employers are planning to scale back healthcare benefits in 2026, as rising costs — driven largely by expensive weight-loss and speciality drugs — strain corporate budgets, according to a new survey by consulting firm survey, released on Wednesday, found that 51 per cent of companies with 500 or more employees intend to increase cost-sharing, such as higher deductibles and out-of-pocket maximums --- that's a notable jump from the 45 per cent of employers who said they would take similar measures for dramatic rise in popularity — and cost—of GLP-1 weight-loss drugs like Novo Nordisk's Wegovy has become a key pressure point, the consultancy said. "More clients are saying ... 'I don't know how much longer we can sustain covering these medications'," said Alysha Fluno, a pharmacy innovation leader at Mercer, in an some employers have covered GLP-1s hoping for long-term health savings, rising prices are forcing a rethink: "Some employers facing big cost increases in 2026 may feel this coverage is out of reach," Fluno Wegovy and Eli Lilly's Zepbound are listed at USD 1086 and USD 1059, respectively, but many patients pay less through their health to the survey, prescription drug costs jumped 8% last year. Mercer has forecast a 5.8 per cent rise in overall health benefit costs for 2025. Employers are also eyeing alternatives to traditional pharmacy benefit managers (PBMs), according to such as CVS Caremark, Cigna's Express Scripts, and UnitedHealthcare's Optum Rx act as middlemen between drug companies and consumers. They negotiate volume discounts and fees with drug manufacturers on behalf of employers and health plans, create lists of medications that are covered by insurance, and reimburse pharmacies for say they take an undisclosed cut of the discounts they receive rather than sharing them with patients and survey found 40 per cent of employers are considering alternative contracting models for their prescription medicine benefits, such as those that price drugs based on their cost to the pharmacy.- EndsWith inputs from Reuters
